Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial - VBI Vaccines

Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial

October 13, 2021 |

Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial
The Journal of the American Medical Association Network Open
October 2021

View More

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

February 23, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

February 15, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

December 8, 2022

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI